Inferra AI / Company / ACAD
Acadia Pharmaceuticals Inc
ACAD · Health Care
Last earnings Aug 4, 2026
Key results
Revenuequarter
9%
revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE (trofinetide) net product sales of $96.1 million
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
“Acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million,” said Catherine Owen Adams, Chief Executive Officer.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Growthquarter
up 9%
Financial Results Revenues Total revenues comprising of net product sales from NUPLAZID and DAYBUE were $264.6 million, up 9% from the second quarter of 2024.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Net incomequarter
$26.7 million
Net Income For the three months ended June 30, 2025, Acadia reported net income of $26.7 million, or $0.16 per common share, compared to net income of $33.4 million, or $0.20 per common share, for the same period in 2024.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | 9% | — | — |
| Growth | up 9% | — | — |
| Net income | $26.7 million | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome in early Q4 2025 SAN DIEGO, CA, August 6, 2025 – Acadia Pharmaceuticals Inc.”
Classified from the release's primary full-year outlook statement.
Capital allocation
The grant date fair value of such awards is estimated using a Monte Carlo simulation, which includes assumptions such as expected volatility, risk-free interest rate and dividend yield.
In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date.
Event summary
Acadia Pharmaceuticals Inc — Earnings release (2025-08-06)
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome in early Q4 2025 SAN DIEGO, CA, August 6, 2025 – Acadia Pharmaceuticals Inc.”
Revenue — Raised (“Raising”)
“htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome in early Q4 2025 SAN DIEGO, CA, August 6, 2025 – Acadia Pharmaceuticals Inc.”
Revenue — Raised (“raising”)
“Full Year 2025 Financial Guidance Acadia is reiterating its 2025 guidance that was provided on May 7, 2025 with the exception of raising the low end of the guidance range for NUPLAZID net product sales and the related impact on guidance for total revenues:  • Total Revenues (U.”
Classified from the release's primary full-year outlook statement.
Capital allocation
The grant date fair value of such awards is estimated using a Monte Carlo simulation, which includes assumptions such as expected volatility, risk-free interest rate and dividend yield.
SEC original ↗Acadia Pharmaceuticals Inc — 10-Q Quarterly report10-QAug 5, 2026
In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date.
SEC original ↗Acadia Pharmaceuticals Inc — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
” Company Updates • Hosted inaugural R&D Day in June, highlighting nine disclosed programs, with seven Phase 2 or Phase 3 studies expected to initiate during 2025-2026 and five readouts anticipated through 2027, reinforcing momentum behind Acadia’s R&D strategy and pipeline depth.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
receiving a shipment in the second quarter and completed implementation of its planned field force expansion.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
• Appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing extensive commercial and launch experience to lead DAYBUE and Rare franchise expansion.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
, including the planned expansion of the DAYBUE commercial team.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Risks & headwinds
  • Achieved two significant patent litigation wins securing market exclusivity for NUPLAZID; affirming the validity of the composition-of-matter patent for pimavanserin, with an expiry date in 2030, and upholding the formulation patent covering the marketed 34 mg capsule, with an expiry date in 2038.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended June 30, 2025.
SEC original ↗Acadia Pharmaceuticals Inc — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Legal Proceedings 27 Item 1A.
SEC original ↗Acadia Pharmaceuticals Inc — 10-Q Quarterly report10-QAug 5, 2026
Risk and Uncertainties Global economic and business activities continue to face widespread macroeconomic uncertainties, including inflation and monetary supply shifts, recession risks, volatility and disruptions in global credit and financial markets, potential disruptions from geopolitical and military conflicts and related sanctions and tariffs and trade tensions.
SEC original ↗Acadia Pharmaceuticals Inc — 10-Q Quarterly report10-QAug 5, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q2 2026
- 8-KACAD
Sep 24, 2026
- 8-KACAD
Sep 11, 2026
- 10-QACAD
- 8-KACAD
- Q1 2026
- 8-KACAD
May 29, 2026
- 10-QACAD
- 8-KACAD
- 8-KACAD
- Q4 2025
- 8-KACAD
- 10-KACAD
Feb 26, 2026
- 8-KACAD
Feb 25, 2026
- 8-KACAD
Jan 13, 2026
- Q3 2025
- 10-QACAD
- 8-KACAD
- 8-KACAD
- Q2 2025
- 10-QACAD
- 8-KACAD
- Q1 2025
- 8-KACAD
Jun 10, 2025
- 8-KACAD
May 29, 2025
- 8-KACAD
May 20, 2025
- 10-QACAD
- 8-KACAD
- 8-KACAD
Apr 16, 2025
- Q4 2024
- 10-KACAD
Feb 27, 2025
- 8-KACAD
Feb 26, 2025
- Q3 2024
- 8-KACAD
Dec 11, 2024
- 8-KACAD
Nov 20, 2024
- 10-QACAD
- 8-KACAD
- Q2 2024
- 8-KACAD
Sep 23, 2024
Earnings releases
12 documentsPresentations
0 documentsNo presentations for Acadia Pharmaceuticals Inc are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Acadia Pharmaceuticals Inc are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.